Abstract
Clinical trials often involve design issues with mathematically intractable complexity. Being part of multi-phase drug development programs, the trial designs need to incorporate prior information in terms of historical data from earlier phases and available knowledge about related trials. Some trials with inherent limits on data collection may need augmentation with simulated pseudo-data. For planning of interim looks, group sequential and adaptive trials require accurate timeline predictions of reaching clinical milestones involving complex set of operational and clinical models. In general, clinical trial design involves an interactive process involving interplay of models, data, assumptions, insights, and experiences to address specific design issues before and during the trial. This offers a rich context for simulation-centric modeling, the theme of this chapter. We will focus on practical considerations of applying simulation modeling tools and techniques to design and implementation of clinical trials. This will be achieved through two real-life case studies and relevant illustrative examples drawn from literature and our practical experience.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antonijevic Z, Pinheiro J, Fardipour P, Lewis RJ (2010) Impact of dose selection strategies used in phase II on the probability of success in phase III. Stat Biopharm Res 2(4):469–486
Arnold B, Hogan D, Colford J, Hubbard A (2011) Simulation methods to estimate design power: an overview for applied research. BMC Med Res Methodol 11:94
Benda N, Branson M, Maurer W, Friede T (2010) Aspects of modernizing drug development using clinical scenario planning and evaluation. Drug Inf J 44:299–315
Berry SM (ed) (2011) Bayesian adaptive methods for clinical trials. Chapman & Hall/CRC biostatistics series. CRC Press, Boca Raton. 305 p
Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370:1393–1401
Chang M (2011) Monte Carlo simulation for the pharmaceutical industry: concepts, algorithms, and case studies. Chapman & Hall/CRC biostatistics series. CRC Press, Boca Raton
Cui L, Hung HMJ, Wang S (1999) Modification of sample size in group sequential clinical trials. Biometrics 55:853–857
Dmitrienko A, Pukstenis E (2017) Clinical trial optimization using R. Chapman & Hall/CRC biostatistics series. CRC Press, Boca Raton
East 6 (2018) Statistical software for the design, simulation and monitoring clinical trials. Cytel Inc., Cambridge, MA
Evans SR (2010) Fundamentals of clinical trial design. J Exp Stroke Transl Med 3(1):19–27
Friede T, Nicholas R, Stallard N, Todd S, Parsons NR, Valdes-Marquez E, Chataway J (2010) Refinement of the clinical scenario evaluation framework for assessment of competing development strategies with an application to multiple sclerosis. Drug Inf J 44:713–718
Gao P, Ware J, Mehta C (2008) Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat 18:1184–1196
Haddad T, Himes A, Thompson L, Irony T, Nair R (2017) Incorporation of stochastic engineering models as prior information in Bayesian medical device trials. J Biopharm Stat 27:1089–1103
Ibrahim JG, Chen M-H, Gwon Y, Chen F (2015) The power prior: theory and applications. Stat Med 34(28):3724–3749
Jennison C, Turnull BW (2000) Group sequential methods with applications to clinical trials. Chapman and Hall/CRC, London
Jiang Z, Song Y, Shou Q, **a J, Wang W (2014) A Bayesian prediction model between a biomarker and clinical endpoint for dichotomous variables. Trials 15:500
Kim K, Tsiatis AA (1990) Study duration for clinical trials with survival response and early stop** rule. Biometrics 46:81–92
Lan KKG, DeMets DL (1983) Discrete sequential boundaries for clinical trials. Biometrika 70:659–663
Mehta CR, Pocock SJ (2011) Adaptive increase in sample size when interim results are promising: a practical guide with examples. Stat Med 30:3267–3284
Muller P, Berry D, Grieve A, Smith M, Krams M (2007) Simulation-based sequential Bayesian design. J Stat Plann Inference 137:3140–3150
Musgrove D, Haddad T (2017) BayesDP: tools for the Bayesian discount prior function. https://Cran.R-project.org/package=bayesDP
Paux G, Dmitrienko A (2016) Mediana: clinical trial simulations. R package version 1.0.4. http://gpaux.github.io/Mediana/
Robert C, Casella G (2010) Introducing Monte Carlo methods with R. Springer, New York
Suess E, Trumbo B (2010) Introduction to probability simulation and Gibbs sampling with R. Springer, New York
Thompson JR (1999) Simulation: a modeler’s approach. Wiley, New York
Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA (2017) Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 390(10108):2160–2170
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Ankolekar, S., Mehta, C., Mukherjee, R., Hsiao, S., Smith, J., Haddad, T. (2020). Monte Carlo Simulation for Trial Design Tool. In: Piantadosi, S., Meinert, C. (eds) Principles and Practice of Clinical Trials. Springer, Cham. https://doi.org/10.1007/978-3-319-52677-5_251-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-52677-5_251-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52677-5
Online ISBN: 978-3-319-52677-5
eBook Packages: Springer Reference MathematicsReference Module Computer Science and Engineering
Publish with us
Chapter history
-
Latest
Monte Carlo Simulation for Trial Design Tool- Published:
- 27 November 2020
DOI: https://doi.org/10.1007/978-3-319-52677-5_251-2
-
Original
Monte Carlo Simulation for Trial Design Tool- Published:
- 19 August 2020
DOI: https://doi.org/10.1007/978-3-319-52677-5_251-1